|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2004-7-5
|
|
pubmed:abstractText |
C225 anti-EGFR (epidermal growth factor receptor) antibody has been shown to enhance tumor response to radiation and a number of chemotherapeutic agents. Because of increased use of concurrent chemoradiotherapy in cancer treatment, it is important to determine whether C225 enhances also the antitumor efficacy of radiation when combined with chemotherapy. This study assessed the effect of C225 on tumor response when combined with docetaxel plus single or fractionated radiation.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0360-3016
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
59
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1163-73
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:15234052-Animals,
pubmed-meshheading:15234052-Antibodies, Monoclonal,
pubmed-meshheading:15234052-Drug Synergism,
pubmed-meshheading:15234052-Female,
pubmed-meshheading:15234052-Humans,
pubmed-meshheading:15234052-Mice,
pubmed-meshheading:15234052-Mice, Nude,
pubmed-meshheading:15234052-Neoplasms,
pubmed-meshheading:15234052-Radiation-Sensitizing Agents,
pubmed-meshheading:15234052-Taxoids,
pubmed-meshheading:15234052-Transplantation, Heterologous
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
C225 antiepidermal growth factor receptor antibody enhances the efficacy of docetaxel chemoradiotherapy.
|
|
pubmed:affiliation |
Department of Experimental Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
